VENXXIVA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VENXXIVA (VENXXIVA).
Venetoclax is a selective inhibitor of B-cell lymphoma-2 (BCL-2), an anti-apoptotic protein overexpressed in various hematologic malignancies. By binding to BCL-2, venetoclax displaces pro-apoptotic proteins like BIM, leading to mitochondrial outer membrane permeabilization and activation of caspases, resulting in apoptosis.
| Metabolism | Primarily metabolized by CYP3A4. Minor contributions from CYP2C8, CYP2C9, CYP2C19, UGT1A1, and UGT1A3. |
| Excretion | Primarily hepatic metabolism with biliary excretion of metabolites; renal excretion of unchanged drug accounts for <5%. Fecal elimination accounts for ~60% of total clearance. |
| Half-life | Terminal elimination half-life is 12 hours (range 10-14 hours); permits twice-daily dosing with steady-state achieved within 2 days. |
| Protein binding | 98% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5 L/kg (approximately 35 L in a 70 kg adult), indicating moderate tissue distribution. |
| Bioavailability | Oral bioavailability is 75% (range 70-80%) with food decreasing absorption by 10%. |
| Onset of Action | Oral: 30-60 minutes to detectable serum concentrations; peak effect at 2-4 hours post-dose. |
| Duration of Action | 12 hours; supports twice-daily dosing with sustained therapeutic levels. |
| Molecular Weight | 374.5 |
800 mg orally twice daily with food.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, not recommended due to lack of safety data. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce to 400 mg twice daily. Child-Pugh C: contraindicated. |
| Pediatric use | Not established; safety and efficacy in pediatric patients have not been studied. |
| Geriatric use | No specific dose adjustment; use with caution due to age-related renal impairment. |
| 1st trimester | No human data; animal studies show embryo-fetal toxicity; avoid use in first trimester unless benefit outweighs risk. |
| 2nd trimester | No human data; theoretical risk of fetal harm; use only if clearly needed. |
| 3rd trimester | No human data; potential for adverse effects on fetal development; avoid use near term. |
Clinical note
Comprehensive clinical and safety monograph for VENXXIVA (VENXXIVA).
| Placental transfer | Unknown degree; based on molecular weight (<500 Da) likely crosses placenta; no human data available. |
| Breastfeeding | Unknown if excreted in breast milk; potential for serious adverse reactions in nursing infants; caution advised; consider alternative therapy. |
| Lactation Rating |
■ FDA Black Box Warning
Tumor lysis syndrome (TLS): Risk is highest at initiation and during dose ramp-up. Prophylaxis and monitoring are required; venetoclax is contraindicated for use in patients with CLL/SLL who require dose adjustment for certain drug interactions because of the risk of TLS.
| Serious Effects |
Hypersensitivity to VENXXIVA or any excipientConcomitant use with strong CYP3A4 inducers
| Precautions | Tumor lysis syndrome: risk increased with high tumor burden; ensure prophylaxis and monitoring., Neutropenia: monitor blood counts and manage with dose interruption or growth factors., Infections: increased risk of serious infections., Immunization: avoid live vaccines., Effects on fertility: may impair fertility. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase drug levels. Avoid pomegranate, star fruit, and Seville oranges. High-fat meals may reduce absorption; take on an empty stomach or with a light meal consistently. |
Loading safety data…
| L4 |
| Teratogenic Risk | First trimester: Risk of major malformations (neural tube defects, cardiac anomalies) increased (FDA Category X). Second/third trimesters: Fetal toxicity (oligohydramnios, renal dysfunction, skull ossification defects). Avoid in pregnancy. |
| Fetal Monitoring | Baseline and serial fetal ultrasound for anomalies and growth. Monitor amniotic fluid index. Maternal renal function (serum creatinine, BUN) and electrolytes weekly. |
| Fertility Effects | Reversible impairment of spermatogenesis in males; females may experience menstrual irregularities and reduced ovulation. Discontinue 6 months prior to conception attempts. |
| Clinical Pearls | VENXXIVA is a tyrosine kinase inhibitor approved for chronic myeloid leukemia. Monitor for QT prolongation; obtain ECG at baseline and periodically. Avoid use with strong CYP3A4 inducers/inhibitors; adjust dose accordingly. Myelosuppression is common; monitor CBC frequently. Hepatotoxicity may occur; assess liver function before and during therapy. Venlafaxine interaction increases serotonin syndrome risk; avoid concurrent use. |
| Patient Advice | Take exactly as prescribed; do not stop without consulting your doctor. · May cause fatigue, nausea, or diarrhea; report severe or persistent symptoms. · Avoid grapefruit and grapefruit juice during treatment. · Use effective contraception during and for 2 weeks after last dose. · Report any signs of infection, bleeding, or unusual bruising immediately. · Do not take with St. John's wort or other herbal supplements without approval. · Store at room temperature away from moisture and heat. |